Leprosy situation in endemic states of India and prospects of elimination of the disease.
In India there is a dramatic fall in the prevalence rate (PR) of leprosy, but the new case-detection rate (NCDR) has not been reduced concomitantly. It is the operational efficiency of the National Leprosy Eradication Programme (NLEP) that has led to a significant reduction in the NCDR in Andhra Pradesh and Tamil Nadu. The ratio of PR to NCDR has been declining in these two states and it reveals that elimination could be reached even with the high NCDR level of 3 to 4 per 10000 population, particularly if single skin lesion (SSL) cases are discharged through single dose treatment of rifampicin, ofloxacin and minocycline (ROM). On the other hand, the significant number of cases detected in Bihar and Orissa during modified leprosy elimination campaigns (MLECs) reveals that there are lacunae in operational activities in new case-detection resulting in a large number of undetected cases in the community. Only one-third of the cases are reporting voluntarily. Awareness of leprosy is not adequate to motivate the patients to report voluntarily and complete their treatment, thus underscoring the need for relying on active case-detection so that transmission can be broken and elimination of leprosy achieved. In addition, the influence of socio-economic factors on continued occurrence of leprosy cannot be ruled out. The establishment of a sentinel surveillance system along with a computerized simplified information system to gain in-depth knowledge on the functioning of the NLEP will ensure operational efficiency. In view of this situation, the NLEP should adopt a more realistic approach towards reaching the elimination goal.
Subramanian
M
M
Division of Epidemiology and Statistics, Central Leprosy Teaching and Research Institute, Chengalpattu 603001, Tamil Nadu.
Showkath Ali
M K
MK
Thorat
D M
DM
Muthukumar
M
M
Sathiskumar
E
E
Ramadoss
C
C
Ali Khan
M
M
D003140:Communicable Disease Control / Q000379:methods* / Q000592:standards; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D008297:Male; D008911:Minocycline / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000254:growth & development*; D009313:National Health Programs; D015242:Ofloxacin / Q000627:therapeutic use; D015995:Prevalence; D012293:Rifampin / Q000627:therapeutic use; D012423:Rural Health; D012424:Rural Population; D011795:Surveys and Questionnaires
D007917:Leprostatic Agents; D015242:Ofloxacin; D008911:Minocycline; D012293:Rifampin